-

Viz.ai to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced Chris Mansi, M.D., CEO and Co-Founder, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023 at 7:30am ET in New York, NY.

Dr. Mansi will share Viz.ai’s growth strategy, underpinned by its large and expanding hospital footprint and strong momentum in its life sciences business with collaborations with 7 of the 30 top global life science companies.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai Platform is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz.ai Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information, visit viz.ai.

Contacts

Ariane Lovell
ariane.lovell@finnpartners.com

Industry:

Viz.ai, Inc.

Release Versions
English
Hashtags
#ai
#aiinhealthcare
#carecoordination
#partnerships

Contacts

Ariane Lovell
ariane.lovell@finnpartners.com

Social Media Profiles
Viz.ai
Viz.ai
More News From Viz.ai, Inc.

Viz.ai and NCCN Collaborate to Integrate NCCN Guidelines into Clinical Workflows for Oncologists

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced an agreement with the National Comprehensive Cancer Network® (NCCN®). This collaboration integrates NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast, Prostate, and Bladder Cancer into the Viz Oncology Platform making this important information readily available to clinicians when they’re making critical decisions about patient care. Thr...

Viz.ai Appoints Dr. Timothy N. Showalter as First Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the appointment of Tim Showalter, MD, MPH, MBA, as its first Chief Medical Officer (CMO). Dr. Showalter, an accomplished academic radiation oncologist, will lead Viz.ai’s clinical strategy and advance the company’s mission to use artificial intelligence to improve access to life-saving care. He will report to Chris Mansi, MD, CEO and co-founder of Viz.ai. Dr. Sho...

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...
Back to Newsroom